文献速递甲状腺疾病

结构倍增时间可预测接受分子靶向治疗的快速进展转移性甲状腺髓样癌患者的总生存期

Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies.
PubMed 文献 · Thyroid · 2020-04-20

这项回顾性研究评估了转移性甲状腺髓样癌(MTC)患者初始手术后结构性疾病进展对总生存期(OS)的影响,以肿瘤体积倍增时间(TVDT)作为结构性疾病进展的标志。结果显示,MTC转移灶的肿瘤生长恒定,与转移部位无关;中位倍增时间(midDT)≤1年者预后差于midDT更高者(p=0.002),midDT≤1年者中位OS为11.1年(CI 7.4-14.8年),midDT 1-3年者为16.5年(CI 10.3-22.6年),midDT≥3年者随访结束时全部存活。初步结果提示测量midDT可预测分子靶向治疗的疗效。

要点

  • MTC转移灶的肿瘤生长恒定,与转移部位无关。
  • midDT≤1年者预后差于midDT更高者(p=0.002)。
  • midDT≤1年者中位OS为11.1年(CI 7.4-14.8年),midDT 1-3年者为16.5年(CI 10.3-22.6年)。

核心结论

  • TVDT是复发或转移性MTC患者OS的强预测因子,可作为进展的标志,并可能有助于筛选可能从分子靶向治疗中获益的患者。

研究设计与样本

  • 回顾性研究,评估初始手术后转移性MTC患者的结构性疾病进展对OS的影响。

主要发现

  • MTC转移灶的肿瘤生长恒定,与转移部位无关。
  • 肺转移的相关系数(r)为0.91、决定系数(r2)为0.95,肝转移的r为0.88、r2为0.94,颈部转移的r为0.73、r2为0.85。
  • midDT≤1年者预后差于midDT更高者(p=0.002)。
  • midDT≤1年者中位OS为11.1年(CI 7.4-14.8年),midDT 1-3年者中位OS为16.5年(CI 10.3-22.6年)。
  • midDT≥3年者随访结束时全部存活。

关键数值与推荐

  • midDT≤1年者中位OS为11.1年(CI 7.4-14.8年),midDT 1-3年者中位OS为16.5年(CI 10.3-22.6年)。
  • midDT≤1年者预后差于midDT更高者(p=0.002)。

临床怎么用

  • TVDT可作为复发或转移性MTC患者OS的强预测因子和进展标志,并可能有助于筛选可能从分子靶向治疗中获益的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose: To evaluate the impact of structural disease progression of metastatic lesions after initial surgery on overall survival (OS) of patients presenting with metastatic medullary thyroid cancer (MTC). We used tumor volume doubling time (TVDT) as a marker of structural disease progression and aimed to correlate the average structural tumor volume doubling time (midDT) with OS in MTC patients after initial surgery. Methods: In this retrospective study, we examined the clinical characteristics; average tumor volume doubling times of neck, lung, and liver metastasis; and disease-specific survival of patients with metastatic MTC. Results: Tumor growth is constant in MTC metastasis, irrespective of location of the metastasis. The median correlation coefficient (r) and the coefficient of determination (r2) were similar in lung metastasis (r = 0.91, r2 = 0.95) and liver metastasis (r = 0.88, r2 = 0.94), and comparable in neck metastasis (r = 0.73, r2 = 0.85). Patients with metastatic MTC with a midDT ≤1 year have a worse prognosis than those with higher midDT (p = 0.002). Those with midDT ≤1 year had a median OS of 11.1 years [confidence interval (CI) 7.4-14.8 years]. In contrast, patients with midDT 1-3 years had a median OS of 16.5 years [CI 10.3-22.6 years]. All patients with midDT ≥3 survived by the end of the follow-up period. Preliminary results suggest that measurement of midDT can predict response to molecular targeted therapies. Conclusions: In conclusion, TVDT is a strong predictor of OS in patients with recurrent or metastatic MTC, can be used as a marker of progression, and potentially can help select patients who may benefit from molecular targeted therapy.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Yeh T, Yeung M, Sherman EJ, et al. Structural Doubling Time Predicts Overall Survival in Patients with Medullary Thyroid Cancer in Patients with Rapidly Progressive Metastatic Medullary Thyroid Cancer Treated with Molecular Targeted Therapies. Thyroid. 2020. PMID: 32131709. doi:10.1089/thy.2019.0579

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。